SARS-CoV-2 in a Patient with Persistent Asthma Taking Omalizumab: The First Case in Turkey

Atayık, Emel; Aytekin, Gökhan

doi:10.21911/aai.574

Cited by 2 publications

(2 citation statements)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, omalizumab also has an indication for use in chronic urticaria. Apart from these effects, both medications have been shown to have some antiviral effects (6). In this case series, we aimed to discuss potential protective effects of these agents against household SARS-CoV-2 transmission in the light of the literature by reporting six different patients who remained uninfected despite PCR (Polymerase Chain Reaction) (+) SARS-CoV-2 individuals at home and were being treated with monoclonal antibodies for chronic urticaria or severe persistent asthma.…”

Section: Introductionmentioning

confidence: 99%

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Atayık¹,

Aytekin

2022

Journal of Health Sciences and Medicine

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is the general term used for pneumonia caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Keeping the infected individuals in quarantine is very effective in preventing the spread of the disease but isolation and quarantine period increase the risk of household transmission. By December 2020, the rate of household transmission of SARS-CoV-2 has reached up to 85%. Both omalizumab and mepolizumab are used for the treatment of severe persistent asthma. In addition, omalizumab also has an indication for use in chronic urticaria. Both medications have been shown to have some antiviral effects. So, we aimed to discuss potential protective effects of these agents against household transmission of SARS-CoV-2 by reporting six different patients who remained uninfected despite PCR (Polymerase Chain Reaction) (+) SARS-CoV-2 individuals at home and were being treated with monoclonal antibodies.

show abstract

Section: Introductionmentioning

confidence: 99%

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Atayık¹,

Aytekin

2022

Journal of Health Sciences and Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, these factors have led to SARS-CoV-2-related fear, worry and anxiety in patients (6). Patients with severe asthma are at particularly higher risk for SARS-CoV-2 infection due to exacerbations of asthma caused by viral infections, increased SARS-CoV-2 viral load at hospitals and challenges in access to healthcare facilities due to several restric¬tions (7)(8)(9). However, it has been revealed out that many patients hindered their treatments or did not present asthma outpatient clinics and that they, therefore, did not receive particularly their monoclonal antibody therapy due to the restrictions imposed during this period and fear of SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Atayık

Aytekin

2022

Hitit Medical Journal

Self Cite

View full text Add to dashboard Cite

Background: Patients with severe asthma are at particularly higher risk for SARS-CoV-2 infection due to exacerbations of asthma caused by viral infections, SARS-CoV-2 viral load at hospitals and challenges in access to healthcare facilities due to some restrictions. Thus, we aimed to investigate effect of the SARS-CoV-2 pandemic on treatment and control of asthma in patients receiving monoclonal antibody MAb treatment. Methods: The patients, who were using MAb for treatment of for severe persistent asthma, were enrolled. Each patient was asked to fill in a validated Coronavirus anxiety scale and a mini survey. Results: Sixty-two patients (Female: 44; Male: 18), who were given MAb therapy for asthma, were enrolled. Patients’ treatment compliance was 56.5% in March-April-May 2020. Curfew was the most common government-related factors that have influenced patients’ compliance to treatment (35.5%). The most common individual factor was fear of contracting SARS-CoV-2 (40.3%). Exacerbated symptoms and need for additional treatment for asthma were significantly more common in patients, who were not compliant to treatment, compared to the patients adherent to MAb treatment (p: 0.034 and p:0.013) Conclusion: Treatment compliance has reduced in patients, who take MAb treatment, due to both governmental and individual reasons. This has led to more common admissions to emergency department with complaints of asthma and need for an additional treatment. All these findings indicate that patients should maintain their MAb treatments despite the pandemic and that they should minimize the risk of SARS-CoV-2 infection by following the recommendations published in the guidelines.

show abstract

SARS-CoV-2 in a Patient with Persistent Asthma Taking Omalizumab: The First Case in Turkey

Cited by 2 publications

References 13 publications

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Contact Info

Product

Resources

About